drugset / Trial / NCT06998771
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.
Timeline
- Start
- 2025-06-15
- Primary completion
- 2028-06-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | — | Intravenous |
| Subject | JSKN003 | Monoclonal antibody | — | Intravenous |
| Subject | KN026 | Monoclonal antibody | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | Pembolizumab | Unknown | — | Intravenous |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | Trastuzumab | Monoclonal antibody | — | Intravenous |